Princess Anne visits BC
Nurses caught in the middle
Eby wants more from feds
$36M for vaccine injury 
Canadians split on budget
Premier stands by pick
Car insurance fuels inflation
Santos ends comeback bid
Douglas C-54 plane crashes
US TikTok ban sent to Biden
Phish fans enter the Sphere
CN Rail profits fall 
Warriors snakebitten in loss
Iginla off to Europe
Rockets ink prospect
Alleged Tupac killer in court
Lawsuit accuses Megan
Bam Margera’s tour axed
The parent company of marijuana producer Organigram Inc. has closed a $10-million investment deal with Hyasynth Biologicals, boosting its access to biotechnology that can produce cannabis' active chemical ingredients in a lab without needing a costly grow-op.
Organigram says Hyasynth's proprietary technology can produce active ingredients that occur naturally in the cannabis plant, called phytocannabinoids, using genetically engineered strains of yeast in a technique known as biofermentation.
The Montreal-based biotech's enzymes and yeast strains have enabled them to produce cannabinoids such as cannabidiol, known as CBD, which can be used for cannabis-based products such as beverages or pharmaceutical products.
The CEO of Moncton-based Organigram, Greg Engel, said the technology is a game-changer, and the investment is aimed at helping Hyasynth scale up to commercial production in the coming months.
"There's always going to be a place for that premium grown product," he said in an interview. "But when you start to look at how cannabinoids are going to be produced in the future for various edibles, vapourizable products, etc. This is infinitely scalable at a fraction of the cost."
Engel says the technology involves inserting a gene into yeast, and growing it over three to five days into a precursor molecule for cannabinoids. Hyasynth then uses proprietary enzymes to convert that molecule into various cannabinoids.
Organigram's investment comes as Canada prepares for the legalization of recreational cannabis on Oct. 17. While fresh or dried cannabis, cannabis oil and plants and seeds will be available this fall, edibles, beverages and topical products using cannabinoids such as CBD and THC won't be legal until 2019. Still, many cannabis companies are preparing to produce these more sophisticated value-added cannabis-based products, which will likely command higher profit margins than dried bud.
